Rating History for Marker Therapeutics (MRKR) by Brookline Capital Markets

More Stocks Rated by Brookline Capital Markets | Latest Ratings for MRKR
Date Analyst Type Rating
(Past)		 PT
(Past)		 Start $
(End $)		 % Chg. Details
1/5/2026 Leah Rush Cann Maintain Buy
(N/A)		 5.60
(4.00)		  
 		   Details